Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD

NCT ID: NCT02251743

Last Updated: 2020-09-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 144 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2020-08-31

Brief Summary

Additional treatments with long-term benefit for attention-deficit/hyperactivity disorder (ADHD) are needed; one of the more promising is neurofeedback (EEG biofeedback), which has several randomized controlled trials showing significant benefit, but which are inconclusive because they were not double-blinded; the benefit could have been nonspecific (placebo response). Because of neurofeedback's labor-intensive cost (1 treatment costing as much as a month's medication), It is important to know how much specific benefit it yields. This 2- site placebo-controlled double-blind randomized clinical trial is the first to test for a specific benefit of neurofeedback with adequate power, the first designed and implemented collaboratively by experts in neurofeedback, ADHD, and clinical trials, the first to rigorously monitor quality not only of treatment, but also of placebo and blinding, and the first to follow up for 2 years to examine enduring effect; the results, whether positive or negative, will provide evidence for clinical practice and public policy regarding ADHD.

Detailed Description

Current established, evidence-based treatments for attention-deficit/hyperactivity disorder (ADHD) are incompletely effective and not universally acceptable, and appear to wane in effect over time despite significant immediate benefit. E.g., FDA-approved medication, which shows large acute benefit, leaves a third of children only partially treated even when combined with behavioral treatment, and has not been demonstrated effective beyond 2 years. Additional treatments are needed that are effective with persisting benefit, preferably related to a biomarker predicting treatment response. A good candidate is electroencephalographic (EEG) biofeedback, called neurofeedback (NF). It is based on 1) observations that patients with ADHD often have excessive theta band (4-8 Hz) quantitative EEG power, low beta band (13-21 Hz) power, and excessive theta beta ratio (TBR), and 2) theoretical application of operant conditioning to correct this EEG imbalance. Metaanalysis of 6 randomized clinical trials found a large benefit for inattentive symptoms and medium benefit for hyperactive-impulsive symptoms. Unfortunately, none of these were blinded. Three of 4 small blinded studies found no advantage for NF over sham, but used suboptimal NF, leaving the situation inconclusive. Because of the expense and time required by NF, there is a public health need to determine whether it has a specific effect beyond the obvious nonspecific benefit of doing a focused activity several times a week with a friendly,encouraging adult who reinforces for attending to the task. Experts in NF, ADHD, clinical trials, statistics, and data management have joined to design a double-blind sham-controlled randomized clinical trial to answer several pressing scientific and clinical questions in a way that will be credible to all. At each of 2 sites (1 university & 1 NF clinic) 70 children (total N=140) age 7 through 10 with rigorously diagnosed moderate to severe ADHD and TBR>5 will be randomized in a 3:2 ratio to active TBR downtraining by NF vs. a sham training of equal duration, intensity, and appearance. To keep both participants and study staff blind, the sham will utilize pre-recorded EEGs with the participant's artifacts superimposed. The sham will be programmed into the equipment via internet by an off-site statistician-guided person who has no contact with participants. Treatment fidelity will be trained and monitored by 2 acknowledged NF leaders in a manner that protects blinding. Multi-domain assessments at baseline, mid-treatment, treatment end, and follow-ups at 6 months, 1 year, and 2 years will include parent and teacher ratings of symptoms & impairment, neuropsychological tests,clinician ratings, and quantitative EEG as well as tests of blinding and of sham inertness. Hypotheses include that NF will improve parent- and teacher-rated inattentive symptoms (primary outcome) and other outcomes more than sham,that benefit will persist for 2 years after training, that initial TBR will moderate treatment response, and that change in TBR will mediate response. Research Domain Criteria and EEG brain changes will be explored, including relationship of TBR to clinical symptoms, executive-function impairment, and sleep.

Conditions

Attention-Deficit/Hyperactivity Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Neurofeedback treatment

The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.

Group Type: EXPERIMENTAL

Neurofeedback treatment

Intervention Type: DEVICE

Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:

1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)

2. Average voltage of theta waves

3. Average voltage of beta

4. Average ratio of theta to beta power (TBR)

Sham neurofeedback treatment

Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show "training progress" over successive sessions, like real NF.

Group Type: PLACEBO_COMPARATOR

Neurofeedback treatment

Intervention Type: DEVICE

Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:

1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)

2. Average voltage of theta waves

3. Average voltage of beta

4. Average ratio of theta to beta power (TBR)

Interventions

Neurofeedback treatment

Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:

1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)

2. Average voltage of theta waves

3. Average voltage of beta

4. Average ratio of theta to beta power (TBR)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Boys and girls age 7 to 10
• IQ>80
• diagnosed DSM-5 ADHD inattentive presentation or combined presentation
• an item mean ≥1.5 sd above norms on a 0-3 metric both on parent ratings of either DSM-IV inattentive symptoms or all 18 ADHD symptoms and on teacher ratings of either inattentive symptoms or all 18 ADHD symptoms
• an eyes-open QEEG with theta-beta power ratio >4.5 at Cz or Fz

Exclusion Criteria

• comorbid disorder requiring psychoactive medication other than FDA-approved ADHD medication
• a medical disorder requiring systemic chronic medication with confounding psychoactive effects
• sleep apnea
• restless legs syndrome
• IQ <80
• plans to move requiring school change during the next 3 months
• plans to start other ADHD treatment in the next 3 months
• antipsychotic agent in the 6 months prior to baseline assessment
• fluoxetine in the 4 weeks prior to baseline
• other psychiatric medication in the two weeks prior to baseline

->5 previous NF treatments

• Vitamin D deficiency will be a temporary exclusion

• Minimum Eligible Age: 7 Years
• Maximum Eligible Age: 10 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

University of North Carolina

OTHER

Sponsor Role: collaborator

Ohio State University

OTHER

Sponsor Role: lead

Responsible Party

L. Eugene Arnold

Professor Emeritus of Psychiatry

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

L. Eugene Arnold, MD, MEd

Role: PRINCIPAL_INVESTIGATOR

The Ohio State University Nisonger Center

Roger deBeus, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of North Carolina at Asheville

Locations

University of North Carolina at Asheville

Asheville, North Carolina, United States

The Ohio State University Nisonger Center

Columbus, Ohio, United States

Countries

United States

References

Ging-Jehli NR, Painter QA, Kraemer HA, Roley-Roberts ME, Panchyshyn C, deBeus R, Arnold LE. A diffusion decision model analysis of the cognitive effects of neurofeedback for ADHD. Neuropsychology. 2024 Feb;38(2):146-156. doi: 10.1037/neu0000932. Epub 2023 Nov 16.

Reference Type: DERIVED

PMID: 37971859 (View on PubMed)

Ging-Jehli NR, Kraemer HC, Eugene Arnold L, Roley-Roberts ME, deBeus R. Cognitive markers for efficacy of neurofeedback for attention-deficit hyperactivity disorder - personalized medicine using computational psychiatry in a randomized clinical trial. J Clin Exp Neuropsychol. 2023 Mar;45(2):118-131. doi: 10.1080/13803395.2023.2206637. Epub 2023 May 8.

Reference Type: DERIVED

PMID: 37157126 (View on PubMed)

Roley-Roberts ME, Pan X, Bergman R, Tan Y, Hendrix K, deBeus R, Kerson C, Arns M, Ging Jehli NR, Connor S, Schrader C, Arnold LE. For Which Children with ADHD is TBR Neurofeedback Effective? Comorbidity as a Moderator. Appl Psychophysiol Biofeedback. 2023 Jun;48(2):179-188. doi: 10.1007/s10484-022-09575-x. Epub 2022 Dec 16.

Reference Type: DERIVED

PMID: 36526924 (View on PubMed)

Neurofeedback Collaborative Group. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: 25-Month Follow-up of Double-Blind Randomized Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2023 Apr;62(4):435-446. doi: 10.1016/j.jaac.2022.07.862. Epub 2022 Dec 12.

Reference Type: DERIVED

PMID: 36521694 (View on PubMed)

Neurofeedback Collaborative Group. Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder With 13-Month Follow-up. J Am Acad Child Adolesc Psychiatry. 2021 Jul;60(7):841-855. doi: 10.1016/j.jaac.2020.07.906. Epub 2020 Aug 25.

Reference Type: DERIVED

PMID: 32853703 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

1R01MH100144-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2013H0417

Identifier Type: -

Identifier Source: org_study_id